Jesse Karpman, MD
Pulmonary Disease · Union, NJNPI 1801997515
Payments from drug & device makers
Across 330 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Bayer$438
- Mylan Specialty L.p.$222
- Actelion Pharmaceuticals US, Inc.$216
- Sanofi$204
- plus $1K from 19 others
What the payments were for
- Food & beverage$5,56099%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 139 | $2,278 |
| AstraZeneca | 50 | $1,114 |
| Bayer | 28 | $438 |
| Mylan Specialty L.p. | 15 | $222 |
| Actelion Pharmaceuticals US, Inc. | 15 | $216 |
| Sanofi | 7 | $204 |
| Viatris Specialty LLC | 11 | $178 |
| Boehringer Ingelheim | 13 | $176 |
| Regeneron Healthcare Solutions, Inc. | 9 | $139 |
| Sunovion Pharmaceuticals Inc. | 8 | $108 |
| Pfizer | 7 | $101 |
| United Therapeutics Corporation | 5 | $78 |
| Philips North America LLC | 4 | $62 |
| Amgen | 3 | $46 |
| Insmed, Inc. | 3 | $43 |
| 3b Medical, Inc. | 2 | $39 |
| Advanced Respiratory, Inc | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Grifols USA, LLC | 2 | $24 |
| Lilly USA, LLC | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$128
- BREZTRI$117
- TRELEGY ELLIPTA$110
- NUCALA$100
How this compares
$5,614 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 61 | $843,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 455 | $381,936 |
| OfevNintedanib Esylate | 13 | $174,084 |
| Breo ElliptaFluticasone/Vilanterol | 366 | $169,017 |
| OpsumitMacitentan | 12 | $147,769 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $105,148 |
| Dupixent PenDupilumab | 17 | $76,534 |
| Dupixent SyringeDupilumab | 11 | $46,288 |
| Spiriva RespimatTiotropium Bromide | 52 | $28,362 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 142 | $21,657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 496 | $16,343 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 50 | $14,707 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $11,806 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $11,180 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $8,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $438 | $843,40261 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta, Anoro Ellipta | $2,278 | $585,857918 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $176 | $209,81880 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $216 | $147,76912 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,114 | $116,328166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Union
- Ilia SegalUnion$18K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.